SCHEMBL5203758

SCHEMBL5203758

Cc1ccc([C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.47
SSTR2 P30874 1/20 0.47
SSTR4 P31391 1/20 0.47
SSTR3 P32745 1/20 0.47
SSTR5 P35346 1/20 0.47
HTR1A P08908 1/20 0.47
TACR2 P21452 3/20 0.46
NT5E P21589 1/20 0.43
PTPN1 P18031 8/20 0.43
CDC25B P30305 6/20 0.43
PTPN2 P17706 3/20 0.43
PTPN11 Q06124 3/20 0.43
PTPN6 P29350 2/20 0.42
GJB2 P29033 1/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19189070 0.91 HTR1A (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL19189222 0.91 HTR1A (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13786301 0.87 HTR1A (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL4956860 0.87 HTR1A (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL12407933 0.86 SLC5A2 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL5207389 0.86 HTR1A (0.46) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL5210512 0.84 HTR1A (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL20643028 0.82 PTPN1 (0.43) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL20643029 0.82 SSTR1 (0.41) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL4956915 0.82 SSTR1 (0.41) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1362855-B1 BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-10-03 EP disclosed
US-7045515-B2 β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2006-05-16 US disclosed
US-20040063929-A1 Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1362855-A1 BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME Kotobuki Pharmaceutical Co., Ltd. (JP) 2003-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063929-A1 Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same HMGCR, NCEH1, CETP SSTR1 3673/4885SSTR2 4485/4885SSTR4 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.